Antengene Announces XPOVIO® Regulatory Approval in Maca

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Macau , Taiwan , Shanghai , China , Australia , Hong Kong , Singapore , South Korea , Chinese , Peter Qian , Asia Pacific , Jay Mei , Prnewswire Antengene Corporation Limited , National Cancer Care Network , Antengene Corporation , International Myeloma Working Group , European Society Of Medical Oncology , Antengene Corporation Limited , Company Annual , Chinese Society Of Clinical Oncology , Administration Bureau Of Macau , Karyopharm Therapeutics Inc , Hong Kong Stock Exchange , Hong Kong China , Macau China , Corporation Limited , Pharmaceutical Administration Bureau , New Drug Application , Chinese Society , Clinical Oncology , Multiple Myeloma , European Society , Medical Oncology , Karyopharm Therapeutics , Kong China , Patients Beyond , Annual Report , Hong Kong Stock ,